MetaVia presents new late-breaking obesity and metabolic data at the ADA 2026 Scientific Sessions supporting DA-1726 differentiation and Vanoglipel combination potential
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at… read more.
